When Evidence Gap Becomes a Commercial Liability
The MENA evidence gap for selected portfolios is becoming a commercial liability for drugmakers that could have been prevented at the design stage.
Hantavirus Is the Warning Signal America Should Not Ignore
Are we genuinely building long-term preparedness infrastructure, or are we repeatedly improvising our way from one outbreak cycle to the next?
presented by
The Power of Real World Data to Study Women’s Health at Scale
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
The AI Drug Discovery Race Is Heating Up, Not In the Way You Think
We should ask a more nuanced question than "does AI work in drug discovery." Rather, we should ask which approaches are about to be proven, and which are about to be exposed, because the field is several bets, and they are not equally sound.
Real-Time Trials Are Here — Now We Need Real-Time Trust
For years the healthcare system has relied on the slow machinery of research — and that system is failing the people it was built for. It was designed for a world that operated with an abundance of caution and lacked the modern tools of today. That world no longer exists.
From Trial-and-Error to Targeted Success: How Computational Disease Models Can Help Patients and Pharma Companies
The in-depth, constantly-changing birds-eye view of disease that computational models provide is an essential next step in linking our ever-expanding clinical knowledge and data with drug development.
Passive Immunization: The Expanding Role of Monoclonal Antibodies in Preventive Medicine
For governments and health systems, monoclonal antibodies represent not just another drug class, but a strategic shift toward precision prevention.
presented by
New Webinar: The Payer AI Readiness Gap: Why Better Data Will Define the Next Era of Health Plan Performance
We'll explore why the next era of payer performance will depend on building a trusted data foundation that connects people, providers, and relationships across the enterprise.
AI Can Accelerate Discovery — Development Still Decides What Advances
AI will continue changing how small molecules are discovered, but the candidates that generate the most interest in silico still have to succeed under real development conditions.
What Life Sciences Companies Get Wrong When Building Cross-Border R&D Structures
These structures, if not set up and managed correctly from day one, can create significant accounting, tax and compliance headaches down the road.
The FDA’s Bayesian Guidance Could Quietly Reshape Clinical Trial Design
New FDA guidance on the use of Bayesian statistics signals a broader shift in accommodating more flexible clinical trial designs and the complexities of diseases such as certain cancers and rare disorders, which may lead to more efficient trials, lower development costs, and faster innovation.
How AI is Unlocking Smarter Clinical Trial Protocols
By fine-tuning domain-specific models with real clinical operations data — such as historical performance, feasibility outcomes, enrollment patterns, and resource utilization — hidden information can be translated into structured intelligence.
presented by
The Healthcare Payments Industry Has a Perception Problem
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
AI in Drug Discovery: Surveying the Breadth of the Challenges
AI can speed up drug discovery and decrease attrition rates in the clinic, but it is important to recognize that both are tall orders. The companies that will benefit most are those that stay grounded, set realistic expectations, and keep experienced scientists at the center of decisions that require genuine creativity and judgment.
Why Patient Engagement Is Clinical Trials’ Next Strategic Frontier
As decentralized trials reduce face time with participants, sponsor organizations that treat engagement as an afterthought will pay for it in dropout rates, missing data and failed endpoints.
What Comes After Pluvicto? A New and Distinct Prostate Cancer Patient Subpopulation Is Taking Shape
The success of Pluvicto has created a new challenge in prostate cancer, one the field has not yet fully named or defined.
Our Aging Population is Forcing a Rethink of How We Design & Package Medicines
Difficult packaging comes with tangible consequences, including lower adherence, higher rates of adverse events, and diminished real-world effectiveness. It can also delay FDA submissions and ultimately, market entry.
The Changing Landscape of New Approach Methodologies
Now more than ever, NAMs need to be considered a core aspect of modern drug development – and scientists, decision-makers, regulators and governments must keep pace with this evolving landscape to ensure they are equipped to deliver the next-generation of therapies.